A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary) ; Cabozantinib; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Nektar Therapeutics
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.
- 31 Oct 2018 Status changed from planning to not yet recruiting.
- 06 Jun 2018 New trial record